Accretion Nutraveda IPO Listing at 48% Premium at ₹191 Per Share

Posted by : sachet | Wed Feb 04 2026

Accretion Nutraveda IPO Listing Today: The Accretion Nutraveda IPO was subscribed 1.83 times at the time of its closing. In this subscription, qualified institutional buyers (QIBs) received 1.01 times, and non-institutional investors (NIIs) received 2.08 times. The retail quota of the issue was subscribed to 33.33%. Before delving deeper into the topic, go through the details of the Accretion Nutraveda IPO.

Table of Contents

Accretion Nutraveda IPO

It is a bookbuilding IPO of ₹24.77 crore, comprising an entirely fresh issue of 0.19 crore shares. The issue will be listed on BSE and SME on its tentative listing date, 2nd February 2026. The Accretion Nutraveda IPO date is scheduled for 28th January 2026 to 30th January 2026. The face value of Accretion Nutraveda shares stands at ₹10 per share, and the IPO Issue price band is set at ₹122 to ₹129 per share

IPO Allotment Date	2nd February 2026
IPO Open Date	28th January 2026
IPO Close Date	30th January 2026
Refund Initiation	3rd February 2026
Issue Size	19,20,000 shares(agg. up to ₹25 Cr)
Face Value	₹10 per share
Lot Size	2,000 Shares
Issue Price	₹122 to ₹129 per share
Issue Type	Bookbuilding IPO
Listing At	BSE SME
Listing Date	4th February 2026

Accretion Nutraveda IPO Listing

On the BSE & SME platforms, Accretion Nutraveda shares are listed at ₹191 per share, reflecting a 48% premium over the issue price of ₹129 per share.

About the Accretion Nutraveda IPO

Accretion Nutraveda Limited was incorporated in 2021. Accretion Nutraveda is involved in the manufacturing of Ayurvedic & Nutraceutical products in various forms, such as tablets, capsules, oral liquids, powders, oils, and external preparations such as balms, creams, and gels. The company is a Contract Development and Manufacturing Organization (CDMO) catering to the domestic as well as international markets such as Sri Lanka, Singapore, and the USA. The products are a blend of traditional Ayurvedic practices and advanced nutraceutical science targeting areas such as liver support, women’s health, bone & joint support, cognitive function, and respiratory wellness.

Business segments:

Domestic Sales & Merchant Exports (Loan License Basis)– accounting for 96.62% of total revenue in FY 2024-25.
Direct Exports– Accounting for 38%, registering steady growth.

It has a manufacturing unit in Gujarat occupying approximately 10,763 sq. ft. with modern infrastructure such as 13 air handling units, processing areas, and quality control mechanisms. The unit is GMP, WHO-GMP, FSSC 22000, ISO 9001:2015, ISO 45001:2018, and Halal certified with FSSAI license.

Accretion Nutraveda Limited Financials

The company’s financial analysis is essential before applying for the Accretion Nutraveda IPO. See the table for Accretion Nutraveda Limited’s financials.

Year Ended	30th Sep 2025 (in cr.)	31st March 2025 (in cr.)	31st March 2024 (in cr.)	31st March 2023 (in cr.)
Assets	16.35	10.86	4.64	4.06
Revenue	14.07	16.06	5.20	3.07
Profit After Tax	2.33	2.61	0.82	0.28
EBITDA	3.29	3.65	1.21	0.59
Net Worth	8.26	5.35	1.08	0.26
Reserves and Surplus	2.95	4.86	0.72	-0.10
Total Borrowings	4.43	3.86	2.17	1.97

Explanation

Accretion Nutraveda Limited’s revenue increased by 208.84% from ₹5.20 crores in March 2024 to ₹16.06 crores in March 2025. Moreover, the company’s PAT increased by 218.29% from ₹0.82 crores in March 2024 to ₹2.61 crores in March 2025.